Free Trial
→ Robinhood warning (From Stansberry Research) (Ad)tc pixel

ImmuPharma (LON:IMM) Stock Price Up 27.3% - Still a Buy?

Written by MarketBeat
October 18, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's stock price surged by 27.3% to GBX 12.60 ($0.17) during trading, despite a 46% drop in trading volume compared to its average.
  • The company reported a negative earnings per share of GBX (0.38) and analysts expect a further compounded decline of -339.0000022 EPS for the current year.
  • ImmuPharma specializes in peptide-based therapeutics, with its lead program, Lupuzor™, targeting Lupus and potentially other autoimmune diseases.
  • Five stocks to consider instead of ImmuPharma.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were up 27.3% on Saturday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares were traded during trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Price Performance

The company has a market capitalization of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53. The stock has a fifty day simple moving average of GBX 7.92 and a 200-day simple moving average of GBX 4.37.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.